FDA Classifies Fibromyalgia Nerve Stimulator as Class II
Published Date: 5/29/2026
Rule
Summary
The FDA is officially classifying the transcutaneous electrical nerve stimulator for fibromyalgia as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get easier access to this innovative treatment by cutting down red tape. The new classification is effective May 29, 2026, and could speed up device availability without extra costs for makers or users.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Device moved to Class II (easier access)
The FDA officially classified the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms as a Class II (special controls) device effective May 29, 2026 (classification applicable May 18, 2022). FDA says this classification reduces regulatory burdens and can enhance patients' access to this treatment and could speed up device availability without extra costs for makers or users.
De Novo device can serve as 510(k) predicate
Because the device was classified via the De Novo process, it can serve as a predicate device for future devices, letting other sponsors use the less-burdensome 510(k) process instead of a De Novo request or premarket approval application.
Device is subject to 510(k) submission now
The document states that transcutaneous electrical nerve stimulators to treat fibromyalgia symptoms are subject to premarket notification under section 510(k) of the FD&C Act at this time (FDA has not determined the device type should be exempt under section 510(m)).
Special controls require safety testing and labeling
FDA established special controls that require non-clinical performance testing (electrical parameter characterization, electrode performance, impedance monitoring), biocompatibility for patient-contacting components, electrical/thermal/mechanical safety and electromagnetic compatibility testing, software verification/validation/hazard analysis, and specific labeling (treatment regimes, electrode shelf life/reuse, device technical summaries, and user instructions).
Device is prescription-only
FDA identifies the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms as a prescription device, meaning patients must receive it through a prescription rather than over-the-counter.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-10621 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Suturing Device for Altering Gastric Anatomy for Weight Loss
The FDA is officially classifying the endoscopic suturing device for weight loss as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative tool faster and ensures it’s safe and effective. The new rules took effect on May 28, 2026, and could save time and money for makers and users alike.
Next: 2026-10709 — Bacillus Thuringiensis Cry1B.34.1, Bacillus Thuringiensis Cry1B.61.1 and Adiantum Trapeziforme var. Braziliense IPD083Cb Proteins; Pesticide Tolerances
The EPA just said it’s okay to have tiny amounts of three special proteins—Cry1B.34.1, Cry1B.61, and IPD083Cb—in all food and animal feed without setting strict limits. This helps farmers and food makers use these proteins safely in crops to protect plants from pests. The new rule kicks in on May 29, 2026, and anyone who wants to object has until July 28, 2026, to speak up.